David F. Hale

David F. Hale is currently Chairman of Hale BioPharma Ventures, LLC, a private company involved in the development of biotechnology, specialty pharma, diagnostic and device companies.  He was previously President and CEO of CancerVax Corporation, which merged with Micromet, Inc., where he served as Chairman until its acquisition by Amgen Inc. in 2012.

David is a serial entrepreneur who has been involved in the formation and development of a number of biomedical companies.  In 1982, after joining Hybritech, Inc., the first monoclonal antibody company, he served as COO, President and then Chief Executive Officer, when Hybritech was acquired by Eli Lilly and Co. in 1986.  From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc., and a co-founder and Chairman of Viagene, Inc. from 1987 to 1995. Prior to joining Hybritech, Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.

Mr. Hale is Chairman of the Board of Santarus, Inc., and Conatus Pharmaceuticals Inc., which are two public biopharmaceutical companies.  He also serves as Chairman of Crisi Medical Systems, Inc., Ridge Diagnostics, Inc., Agility Clinical, Inc., Advantar Laboratories, Inc., Intrepid Therapeutics, Inc., Biocept, Inc., Katama Pharmaceuticals and Colorescience Inc.  He served as Chairman of SkinMedica until its acquisition by Allergan in 2012.  Mr. Hale also serves on the Board of Directors of BIOCOM, the San Diego EDC and he is a co-founder and a director of CONNECT.  He also serves as Chairman of the Board of Trustees of Rady Children’s Hospital.

* Title and professional details reflect status as of 7/1/2025.